Subcutaneous fat necrosis of the newborn is an uncommon disorder, and although usually benign, associated hypercalcemia can lead to complications such as failure to thrive and renal failure. Many sources suggest screening for hypercalcemia for 6 months following resolution of skin lesions, but little data are available to support this recommendation. This study examines existing published literature to better guide practitioners regarding screening evaluations of asymptomatic patients with subcutaneous fat necrosis. A systematic review of the literature was conducted using a PubMed English literature search. Data from case reports and case series were collected regarding the presence of hypercalcemia and associated complications, birth history, and age of onset/resolution of skin lesions and laboratory abnormalities. Approximately half (51%) of infants reported had hypercalcemia. Most (77%) developed detectable hypercalcemia within 30 days of skin lesion onset, and 95% developed detectable hypercalcemia within 60 days of skin lesion onset.
6 months following resolution of skin lesions, but little data are available to support this recommendation. This study examines existing published literature to better guide practitioners regarding screening evaluations of asymptomatic patients with subcutaneous fat necrosis. A systematic review of the literature was conducted using a PubMed English literature search. Data from case reports and case series were collected regarding the presence of hypercalcemia and associated complications, birth history, and age of onset/resolution of skin lesions and laboratory abnormalities. Approximately half (51%) of infants reported had hypercalcemia. Most (77%) developed detectable hypercalcemia within 30 days of skin lesion onset, and 95% developed detectable hypercalcemia within 60 days of skin lesion onset.
Hypercalcemia was detected in only 4% of patients > 70 days following onset of skin lesions. Seventy-six percent had resolution of hypercalcemia within 4 weeks of detection. Hypercalcemia was more prevalent in full-term vs pre-term infants (Pvalue = 0.054), and higher birthweight was significantly associated with an increased risk of developing hypercalcemia (P-value = 0.022). Although gestational age trended toward significance, the only statistically significant clinical feature predicting the development of hypercalcemia was higher birthweight. Current recommendations for laboratory monitoring are not evidence-based, and this study provides interim data to guide practitioners until prospective, randomized controlled trials are conducted.
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| BACKGROUND/ IN TR ODUCTION
Subcutaneous fat necrosis of the newborn (SFNN) is a recognized but uncommon disorder primarily affecting full-term and post-term infants, usually within the first few weeks of life.
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The disorder is characterized by firm, red or purple subcutaneous nodules and plaques on the trunk, buttocks, cheeks, and extremities and is associated with perinatal stress. 3, [5] [6] [7] [8] [9] Although the pathogenesis of the disorder is currently unknown, precipitating factors may include asphyxia, hypothermia/cold exposure, meconium aspiration, hypoxemia, obstetric trauma, and maternal conditions such as preeclampsia and diabetes. We report an illustrative case and review published case series and case reports to better shape guidelines for laboratory screening in infants with subcutaneous fat necrosis. This study constitutes a systematic review of existing literature, as not enough data currently exist in the literature to conduct a true meta-analysis. It is our hope that this review will serve as the first step in furthering the research of hypercalcemia associated with subcutaneous fat necrosis of the newborn and that additional studies with higher levels of evidence will be designed and reported in the literature. Evidence for screening guidelines is generally confined to expert opinion, case reports, and observational or descriptive studies, and evidence from randomized controlled studies is lacking. Additionally, where there has been controversy or lack of consensus, more conservative approaches have been selected until more evidence-based data are available.
| CASE REPORT
A Caucasian female was born at full-term (40 weeks, 2 days) via caesarian section to a 35-year-old G1P0 mother due to poor fetal heart tones. APGARs were 2, 2, and 6 at 1, 5, and 10 minutes, respectively. Soon after birth, the patient experienced severe perinatal asphyxia and required intubation and suction due to the presence of meconium staining. Positive pressure ventilation and positive endexpiratory pressure were also required. The patient did not receive body cooling or therapeutic hypothermia.
The patient was transferred to the Children's Hospital of Wisconsin neonatal intensive care unit on day 2 of life. She sustained an ischemic stroke, suffered an acute kidney injury, and had elevated liver enzymes with a clot noted in the umbilical vein. The patient was initially given antibiotics for a sepsis workup, but these were discontinued when it was discovered that she was suffering from renal insufficiency.
On day 4 of life, the patient's skin was noted to be "blotchy red At 2 months of age, she was again admitted to the hospital due to decreased oral intake and persistent hypercalcemia (11.3 mg/dL).
She had been receiving high doses of prednisolone (1.6 mg/kg/d) for hypercalcemia, leading to hypertension, poor oral intake, and failure to thrive. During this hospital admission, she was switched to bisphosphonates for treatment of hypercalcemia.
Calcium levels initially returned to normal as the subcutaneous fat necrosis resolved, but levels were again slightly elevated at 
| METHODS FOR REVIEW OF THE LITERATURE
A systematic review of the literature was performed. PubMed was the primary search engine utilized, and articles were filtered using the keywords "subcutaneous fat necrosis of the newborn." The search was limited to "case reports" for article type and "English"
for language. Additionally, only articles with full text available were included. The date last searched was October 3, 2017.
When available, the following data were collected from each case 
| RESULTS
In total, 147 articles were screened using PubMed. Of these, 30
were excluded due to lack of access to full-text articles. Of the remaining 117 articles, 23 were excluded for reasons such as incorrect study type (not a case report or case series), lack of numerical data, irrelevant content, and subcutaneous fat necrosis being mentioned only as a differential diagnosis. In all, 94 articles were included for review and data analysis with a total of 127 individual cases of subcutaneous fat necrosis of the newborn (Figure 1 ).
Data regarding the onset of skin lesions were available for 126 patients; of these, 56% (71) had an onset of lesions within the first week of life, and 21% had an onset in the second week of life.
Ninety-two percent had an onset in the first 28 days of life, with only 1 patient experiencing an onset of skin lesions at > 42 days (Figure 2 ). The median age of onset of skin lesions was 6 days.
Fifty-one percent (65) of the reported infants were described as having hypercalcemia. In 56 of these patients, data were available regarding the timing of hypercalcemia detection. Hypercalcemia was detected in the first 28 days of life in 57% of these patients and was detected in the second 28 days of life (29-56 days) in 30% of patients.
Only 2 (4%) patients had hypercalcemia detected after 70 days of age (Table 1 ).
In 77% of the 56 patients with data available for both onset of hypercalcemia and onset of skin lesions, detection of hypercalcemia occurred less than 28 days after the appearance of skin lesions. In fact, detection occurred simultaneously in 23%, and detection occurred prior to the appearance of skin lesions in 2%. Only two patients had hypercalcemia detected > 70 days after skin lesions were noted (Figure 3 ).
Forty-two patients had data available regarding both the onset and resolution of hypercalcemia. Eighty-eight percent of these patients had resolution of hypercalcemia within the first 84 days of life; however, 1 patient still had hypercalcemia at 1 year of age.
Ninety-three percent had a duration of hypercalcemia < 84 days.
The 3 patients (7%) with a known duration of hypercalcemia longer than 84 days had durations of 132 days, 171 days, and 406 days, highlighting that once detected, hypercalcemia can persist. In 48% of patients, hypercalcemia resolved in 2 weeks or less (onset to resolution ≤ 2 weeks). In 29%, the hypercalcemia resolved in 2-4 weeks; 76% had resolution of hypercalcemia within 28 days of detection ( Figure 4 ).
Thirty-five of the 65 (54%) patients noted to have hypercalcemia were reported to have complications or symptoms. Many patients were asymptomatic, and it was unclear if laboratories were checked in all patients. Symptoms of elevated calcium levels included irritability, vomiting, poor feeding, polyuria, hypotonia, failure to thrive, hypertension, persistent nephrocalcinosis, renal dysfunction, and seizures.
In 20% (25) of the cases reviewed, patients were reported as having experienced therapeutic hypothermia or body cooling. Hypercalcemia was reported in 12 (48%) of these cases versus in 52% of patients who did not undergo therapeutic hypothermia or body cooling (P-value = 0.722). Eighty-six percent of patients experienced intrauterine/perinatal distress or pregnancy complications, and many were delivered via caesarian section due to fetal distress.
One hundred and fourteen patients had data available regarding gestational age. The majority of patients (63%) were born at fullterm; 10% were preterm, 11% were early term, 9% were late term, and 7% were post-term. Hypercalcemia was detected in 27% of preterm infants and in 54%, 58%, 50%, and 38% of those born at early term, full-term, late term, and post-term, respectively ( Figure 5 ). The increased prevalence of hypercalcemia in full-term infants versus pre-term infants was not found to be statistically significant (Pvalue = 0.054). The three preterm infants noted to have hypercalcemia were born at 33 weeks + 6 days, 35 weeks, and 36 weeks + 1-day gestation.
Seventy-five patients had data available regarding birthweight.
Of the patients who were noted to have hypercalcemia, the average birthweight was 3833 g; the average birthweight for all other infants was 3455 g (a statistically significant difference, P-value = 0.022).
123 patients had data available regarding gender; 34 of the 65 females developed detectable hypercalcemia versus 29 of the 58 males (not statistically significant; P-value = 0.798).
| DISCUSSION
Subcutaneous fat necrosis of the newborn is increasingly being recognized in the literature with case reports and case series. In line with previous study findings, the majority of the patients included in our review were infants born at full-term, and most (86%) experienced intrauterine or perinatal distress/pregnancy complications.
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This study confirms that subcutaneous fat necrosis of the newborn, especially when associated with hypercalcemia, is less common in preterm infants than in those born at full-term; 27% of preterm infants reported developed hypercalcemia versus 58% of reported full-term infants. Although this difference was not statistically significant (P-value = 0.054), our analysis was limited by a small sample size (83), and the results may still be clinically significant. While some authors suggest that a correlation exists between low birthweight and hypercalcemia, the results of our study instead showed a correlation between higher birthweight and the development of hypercalcemia. 8 Birthweight may represent a better data point than gestational age in predicting which infants will develop hypercalcemia, as it is more accurate than gestational age.
Although the pathogenesis of subcutaneous fat necrosis of the newborn remains unknown, it has been suggested that body cooling may play a role, as the higher ratio of saturated to unsaturated fat in the skin of neonates predisposes to crystallization with hypothermia. 16, 17, [19] [20] [21] [22] [23] With the increased utilization of therapeutic hypothermia in neonates, it is important to look at a possible association of hypercalcemia with its use. However, a slightly lower percentage of patients in the study who underwent body cooling/therapeutic hypothermia developed detectable hypercalcemia (48%) than did those who did not (52%); this difference was not found to be statistically significant (P-value = 0.722). Thus, there does not appear to be a clear association/causality between cooling and hypercalcemia associated with subcutaneous fat necrosis. However, it should be noted that screening laboratory evaluations were not completed in all patients, so asymptomatic hypercalcemia could have been present in some of these cases. Additionally, it is possible that some patients received therapeutic hypothermia or body cooling and that it was not described in the reports. The percentage of patients reported to have detectable hypercalcemia (51%) may also be overstated due to publication/reporting bias.
Subcutaneous fat necrosis is an uncommon, generally benign condition of full-term neonates; however, associated hypercalcemia, when present, can cause significant morbidity and/or mortality. The incidence of hypercalcemia has been reported in previous case series and small reviews, but the incidence reported varies widely. cemia, although only 13 of these patients were evaluated for laboratory abnormalities. The incidence of hypercalcemia was found to be 51% in our study. While it is possible that this number may be elevated due to reporting bias, it is also possible that this number may be understated, as not all patients were monitored for laboratory abnormalities. is aberrantly produced by the granulomatous lesions found in subcutaneous fat necrosis, leading to increased calcium absorption. 1, 6, 9, 15 Others have postulated that calcium is mobilized from resolving areas of subcutaneous fat necrosis. 9, 33 Although not often described in the literature, another possible cause is decreased clearance of calcium by the kidneys; in the case we presented, our patient suffered a kidney injury very early in life. However, no renal dysfunction was described in the four infants in this review reported to have a duration of hypercalcemia >70 days. Akin et al 34 state that hypercalcemia severity is proportional to the width of skin lesions; however, because not all case reports reviewed included exact measurements of lesions, our study could not confirm this. No gender preference for the development of hypercalcemia has been reported in the literature. In our analysis, 52% of females developed hypercalcemia versus 50% of males (not statistically significant; P-value = 0.798), making a clear association between gender and hypercalcemia unlikely.
Recommendations in the literature commonly advise practitioners to screen for hypercalcemia until 6 months after the resolution of skin lesions, 5, 8, [35] [36] [37] [38] [39] [40] [41] [42] with a less common recommendation being to monitor for the first 6 weeks of life following a diagnosis of subcutaneous fat necrosis. 14 However, little evidence supports these guidelines. In the cohort of patients analyzed in this study, 76% had resolution of hypercalcemia within 28 days of its detection. Moreover, elevated calcium levels were detected in only 4% of patients more than 70 days following the onset of skin lesions; 95% of patients developed detectable hypercalcemia within 60 days of the onset of skin lesions. These findings suggest that the current recommendation of monitoring asymptomatic infants for hypercalcemia for 6 months following the resolution of skin lesions may be overly conservative.
Based on our review and current understanding of the disease, we recommend screening for hypercalcemia at diagnosis of subcutaneous fat necrosis and again at 30, 45, and 60 days following resolution of skin lesions. Children who exhibit signs or symptoms of hypercalcemia within 6 months of skin lesion resolution should also be screened.
While no guidelines exist regarding ordering of specific laboratories, we recommend obtaining both total serum calcium and ionized calcium levels, as ionized calcium-the free, active form of calcium that has physiologic effects-can vary based on pH and albumin levels.
Because 76% of patients analyzed in this study had resolution of hypercalcemia within 28 days of detection, for children with mildly elevated hypercalcemia, we recommend weekly screening for 4 weeks or until resolution of hypercalcemia, whichever occurs first. Due to the retrospective nature of this review, we recommend rechecking calcium levels in all patients who develop signs or symptoms of hypercalcemia within 6 months of skin lesion resolution. Reports indicate that patients often become symptomatic at or above total serum calcium levels of 12 mg/dL or ionized calcium levels of 8 mg/dL, defined as moderate hypercalcemia. Hypercalcemic crisis, a medical emergency, is defined as total serum calcium ≥ 14 mg/dL or ionized calcium ≥ 10 mg/dL. 43, 44 To be conservative, we recommend increased surveillance-twice weekly laboratory testing-for patients with total serum calcium ≥ 12 mg/dL until further evidence-based studies are conducted, and we recommend inpatient monitoring with further workup for patients meeting criteria for hypercalcemic crisis.
Due to the risks of untreated hypercalcemia, parents should be advised about the symptoms of hypercalcemia and instructed to see a physician if any such symptoms develop, especially within the first few months of diagnosis of subcutaneous fat necrosis. Prospective, highly structured studies analyzing the incidence and duration of hypercalcemia are needed to establish evidence-based guidelines for laboratory monitoring. However, our systematic review of the literature-the largest to date to the best of our knowledge-provides interim guidance for practitioners.
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